If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
medical genetics The branch of medicine and medical science that involves the study, diagnosis, and management of hereditary disorders, and more broadly the application of knowledge about human genetics to medical care.
Adrenocortical carcinoma (ACC) is an aggressive cancer originating in the cortex (steroid hormone-producing tissue) of the adrenal gland. Adrenocortical carcinoma is remarkable for the many hormonal syndromes that can occur in patients with steroid hormone-producing ("functional") tumors, including Cushing's syndrome, Conn syndrome, virilization, and feminization. Adrenocortical carcinoma has often invaded nearby tissues or metastasized to distant organs at the time of diagnosis, and the overall 5-year survival rate is about 50%. Adrenocortical carcinoma is a rare tumor, with incidence of one to two per million population annually. It has a bimodal distribution by age, with cases clustering in children under 5 and in adults 30–40 years old. The widely used angiotensin-II-responsive steroid-producing cell line H295R was originally isolated from a tumor diagnosed as adrenocortical carcinoma. Adrenocortical carcinoma can occur at any age, with the highest incidence between 40 and 60 years of age. Women are more frequently affected (55 to 60%) than men (40 to 45%). Adrenocortical carcinomas usually occur sporadically in adults. However, they sometimes occur as part of hereditary syndromes, such as:
== Conquest of Sumer == Eannatum, grandson of Ur-Nanshe and son of Akurgal, was a king of Lagash who conquered all of Sumer, including Ur, Nippur, Akshak (controlled by Zuzu), Larsa, and Uruk (controlled by Enshakushanna, who is on the King List). He entered into conflict with Umma, waging a war over the fertile plain of Gu-Edin. He personally commanded an army to subjugate the city-state, and vanquished Ush, the ruler of Umma, finally making a boundary treaty with Enakalle, successor of Ush, as described in the Stele of the Vultures and in the Cone of Entemena:
For all intents and purposes, the terms "IMTA" and "integrated aquaculture" differ only in their degree of descriptiveness. Aquaponics, fractionated aquaculture, integrated agriculture-aquaculture systems, integrated peri-urban-aquaculture systems, and integrated fisheries-aquaculture systems are other variations of the IMTA concept.
Sources: en.wikipedia.org
dopaquinone → leucodopachrome → dopachrome → 5,6-dihydroxyindole-2-carboxylic acid → quinone → eumelanin dopaquinone → leucodopachrome → dopachrome → 5,6-dihydroxyindole → quinone → eumelanin Detailed metabolic pathways can be found in the KEGG database (see External links).
Chancellor Rachel Reeves conducts a spending review in which she limits winter fuel payments to pensioners receiving pension credit (affecting around 10 million people), and announces the cancellation of several infrastructure projects. Reeves argues she has had to make "necessary and urgent decisions" because of an "unfunded" and "undisclosed" overspending of £21.9bn by the previous government. The shadow chancellor, Jeremy Hunt, disagrees with Reeves, saying that when his party was in power there were no hidden overspends and that the government had been open about public finances. Hunt says Reeves misled the country knowing "taxes will have to go up, and she chose not to tell us". He predicts that her first Budget will be the "biggest betrayal in history by a new chancellor". The new Labour government scraps the controversial proposed Stonehenge road tunnel. 2024 Summer Olympics: The first gold medal for Team GB is won by Laura Collett in the final round of show jumping. Tom Pidcock wins a second in mountain biking later in the day. A judge issues an arrest warrant for Tommy Robinson after he left the UK via Eurotunnel on the eve of a major court case against him. Former BBC newsreader Huw Edwards is charged with making indecent images of children. The High Court rules that the previous government's use of emergency legislation to ban puberty blockers is lawful. 30 July 2024 Southport stabbing: The three young girls killed in the attack are named as Bebe King, aged 6; Elsie Dot Stancombe, aged 7; and Alice Dasilva Aguiar, aged 9.
== Research == Other related drugs under development by Helus Pharma (formerly Cybin) include the deuterated phenethylamine HLP005 (CYB005) and the deuterated tryptamines deupsilocin (HLP003; CYB003) and deudimethyltryptamine (HLP004; CYB004).
== External links == "P2Y Receptors: P2Y1". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2008-12-09. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Legal actions taken by those involved in nuclear industries, including miners, millers, transporters, nuclear site workers, and their respective unions have resulted in compensation for those affected by radon and radiation exposure under programs such as the compensation scheme for radiation-linked diseases (in the United Kingdom) and the Radiation Exposure Compensation Act (in the United States).
Sources: en.wikipedia.org
=== Pulse experiments === This method required the introduction of a very small volume of concentrated tracer at the inlet of the reactor, such that it approaches the Dirac delta function. Although an infinitely short injection cannot be produced, it can be made much smaller than the mean residence time of the vessel. If a mass of tracer,
The adaptor hypothesis implies that the actual set of twenty amino acids found in proteins is due either to a historical accident or to biological selection at an extremely primitive stage."Crick admitted that he had no way knowing what kind of chemical substance was an adaptor, but then prudently suggested that it was composed of nucleotides, a sort of RNA, that had common features of both DNA and RNA. He even speculated that "insulin, for example, are probably RNA-made proteins. Perhaps a special class of DNA-made proteins exists, almost always in small quantities (and thus normally overlooked). The template could consist of perhaps a single chain of RNA…Each adaptor molecule containing, say, a di- or trinucleotide would each be joined to its own amino acid by a special enzyme. These molecules would then diffuse to the microsomal particles and attach to the proper place on the basis of the RNA by base-pairing.The article circulated to the members of the RNA Tie Club in January 1955 as "On Degenerate Templates and the Adaptor Hypothesis: A Note for the RNA Tie Club" is described as "one of the most important unpublished articles in the history of science", and "the most famous unpublished paper in the annals of molecular biology." The adaptor hypothesis was fully formalised in 1957. Crick presented the elaborate explanation in a lecture titled "Protein synthesis" on 19 September 1957 at the Society for Experimental Biology symposium on the Biological Replication of Macromolecules, held at University College London.
==== MeSH D13.695.667 – purine nucleotides ==== MeSH D13.695.667.138 – adenine nucleotides MeSH D13.695.667.138.124 – adenosine diphosphate MeSH D13.695.667.138.124.070 – adenosine diphosphate sugars MeSH D13.695.667.138.124.070.075 – adenosine diphosphate glucose MeSH D13.695.667.138.124.070.125 – adenosine diphosphate ribose MeSH D13.695.667.138.124.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.667.138.124.070.125.195 – cyclic adp-ribose MeSH D13.695.667.138.180 – adenosine monophosphate MeSH D13.695.667.138.180.080 – adenosine phosphosulfate MeSH D13.695.667.138.236 – adenosine triphosphate MeSH D13.695.667.138.236.050 – adenylyl imidodiphosphate MeSH D13.695.667.138.236.250 – ethenoadenosine triphosphate MeSH D13.695.667.138.382 – coenzyme a MeSH D13.695.667.138.382.300 – acyl coenzyme a MeSH D13.695.667.138.382.300.020 – acetyl coenzyme a MeSH D13.695.667.138.382.300.500 – malonyl coenzyme a MeSH D13.695.667.138.382.300.700 – palmitoyl coenzyme a MeSH D13.695.667.138.395 – cyclic amp MeSH D13.695.667.138.395.225 – 8-bromo cyclic adenosine monophosphate MeSH D13.695.667.138.395.250 – bucladesine MeSH D13.695.667.138.410 – deoxyadenine nucleotides MeSH D13.695.667.138.506 – flavin-adenine dinucleotide MeSH D13.695.667.138.694 – nad MeSH D13.695.667.138.749 – nadp MeSH D13.695.667.138.850 – phosphoadenosine phosphosulfate MeSH D13.695.667.138.925 – vidarabine phosphate MeSH D13.695.667.454 – guanine nucleotides MeSH D13.695.667.454.160 – cyclic gmp MeSH D13.695.667.454.160.325 – dibutyryl cyclic gmp MeSH D13.695.667.454.200 – deoxyguanine nucleotides MeSH D13.695.667.454.340 – guanosine diphosphate MeSH D13.695.667.454.340.350 – guanosine diphosphate sugars MeSH D13.695.667.454.340.350.400 – guanosine diphosphate fucose MeSH D13.695.667.454.340.350.500 – guanosine diphosphate mannose MeSH D13.695.667.454.440 – guanosine pentaphosphate MeSH D13.695.667.454.480 – guanosine tetraphosphate MeSH D13.695.667.454.504 – guanosine triphosphate MeSH D13.695.667.454.504.380 – guanosine 5'-o-(3-thiotriphosphate) MeSH D13.695.667.454.504.400 – guanylyl imidodiphosphate MeSH D13.695.667.454.525 – 5'-guanylic acid MeSH D13.695.667.454.700 – rna caps MeSH D13.695.667.454.700.710 – rna cap analogs MeSH D13.695.667.616 – inosine nucleotides MeSH D13.695.667.616.300 – cyclic imp MeSH D13.695.667.616.400 – inosine diphosphate MeSH D13.695.667.616.500 – inosine monophosphate MeSH D13.695.667.616.800 – inosine triphosphate
== In popular culture == British actor Bob Hoskins portrayed Manuel Noriega in the biographical 2000 American television movie Noriega: God's Favorite. Noriega was also depicted in the 2012 video game Call of Duty: Black Ops II. In July 2014, he filed a lawsuit against the game company Activision for depicting him and using his name without his permission. Noriega, who filed the suit while in prison for murder, claimed he was portrayed as "a kidnapper, murderer and enemy of the state". On October 28, 2014, the case against Activision was dismissed in California by Judge William H. Fahey.
=== Names === Mesocarb is the generic name of the drug and its INNTooltip International Nonproprietary Name. It is also known by the synonym fensidnimine as well as by the brand names Sydnocarb and Synocarb. The drug is additionally known by its developmental code name MLR-1017 (for Parkinson's disease).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.